clinical trial · NCT04305275
A Study to Evaluate the Efficacy, Safety, and Tolerability of SAGE-324 in Participants With Essential Tremor
Essential TremorSAGE-324SAGE-324 Placebo
brief summary
This is a phase 2, double-blind, placebo-controlled study to evaluate the safety and efficacy of SAGE-324 compared to placebo on upper limb (UL) tremor reduction in individuals with essential tremor (ET).
started
May 19, 2020
primary completion
Feb 1, 2021
completion
Feb 15, 2021
last updated
Apr 17, 2024
official title
A Phase 2, Double-Blind, Placebo-controlled, Randomized Study Evaluating the Efficacy, Safety, and Tolerability of Sage-324 in the Treatment of Individuals With Essential Tremor
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol